Rapid Readout: Expert Perspectives on Multiple Sclerosis - Data from the 8th Joint ACTRIMS-ECTRIMS Meeting 2020

EP. 1: Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 2: OLKIOS: Looking at Ofatumumab’s Continued Efficacy

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 3: OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 4: Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 5: Takeaways From ACTRIMS-ECTRIMS 2020 Meeting

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 6: Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 7: OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 8: OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 9: Ozanimod Compared to Teriflunomide Utilizing Statistical Matching

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 10: Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 11: Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 12: Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 13: CLARITY Extension Trial: Disability Improvement With Cladribine

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 14: COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 15: Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

Trending on NeurologyLive

MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne

Expanding the Alzheimer Drug Development Pipeline

DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point

FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex Deficiency

NeurologyLive® Friday 5 — September 12, 2025

© 2025 MJH Life Sciences^®

All rights reserved.